[{"NetIncomeLoss_1_Q1_USD":-37763000.0,"AccruedLiabilitiesCurrent_0_Q1_USD":22263000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-10224000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q1_USD":4604000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":21762000.0,"Depreciation_1_Q1_USD":1436000.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_1_Q1_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q1_shares":14803056.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":931088810.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q1_USD":-3001000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":535000.0,"CommonStockSharesIssued_0_Q1_shares":932817168.0,"Assets_0_Q1_USD":411581000.0,"ShareBasedCompensation_1_Q1_USD":5334000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":18326000.0,"CommonStockParOrStatedValuePerShare_0_Q1_GBP":0.001,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q1_USD":0.75,"AssetsCurrent_0_Q1_USD":359293000.0,"CommonStockSharesAuthorized_0_Q1_shares":1038249630.0,"GeneralAndAdministrativeExpense_1_Q1_USD":13817000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-223000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-204000.0,"PrepaidExpenseCurrent_0_Q1_USD":5689000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-1000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":298000.0,"CommonStockValue_0_Q1_USD":1331000.0,"ForeignCurrencyTransactionGainLossUnrealized_1_Q1_USD":-1249000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":534000.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1_Q1_USD":0.0,"CostsAndExpenses_1_Q1_USD":38323000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_1_Q1_USD":84646000.0,"OtherAssetsCurrent_0_Q1_USD":2943000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-37939000.0,"InterestIncomeDebtSecuritiesAvailableForSaleOperating_1_Q1_USD":425000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":32432000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":19897000.0,"Liabilities_0_Q1_USD":102424000.0,"IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_1_Q1_USD":-8601000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":24506000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":434000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":285512000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-37465000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":5334000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":3048000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-46540000.0,"LiabilitiesCurrent_0_Q1_USD":31307000.0,"AccountsPayableCurrent_0_Q1_USD":4116000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":37036000.0,"OtherOperatingActivitiesCashFlowStatement_1_Q1_USD":1299000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":41349000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":2459000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q1_USD":1619000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0_Q1_security":0.0,"AdditionalPaidInCapital_0_Q1_USD":941569000.0,"PaymentsToAcquireIntangibleAssets_1_Q1_USD":133000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1_Q1_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":27739000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":534000.0,"OperatingIncomeLoss_1_Q1_USD":-37889000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q1_USD":-176000.0,"PaymentsToAcquireMarketableSecurities_1_Q1_USD":61599000.0,"IncomeTaxesReceivable_0_Q1_USD":31141000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":2083000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":411581000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":5836000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":5334000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":2845000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.04,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q1_USD":32703000.0,"ProfitLoss_1_Q1_USD":-37763000.0,"OtherLiabilitiesCurrent_0_Q1_USD":391000.0,"StockholdersEquity_0_Q1_USD":309157000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q1_USD":50565000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":1152000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-623519000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-24448000.0,"CommonStockSharesOutstanding_0_Q1_shares":932817168.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":655000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":162000.0,"Ticker":"ADAP","CIK":"1621227","name":"ADAPTIMMUNE THERAPEUTICS PLC","OfficialName":"Adaptimmune Therapeutics plc American Depositary Shares","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"301181409.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210506"}]